Dental stem cell-derived extracellular vesicles for oral tissue regeneration: Mechanisms, engineering strategies, and clinical translation.

OBJECTIVE

The regeneration of complex oral and maxillofacial tissues remains a significant clinical challenge. While stem cell-based therapies have shown promise, their clinical translation is impeded by safety concerns, immune rejection risks, and manufacturing standardization hurdles. Cell-free therapies utilizing extracellular vesicles derived from dental mesenchymal stem cells (DMSC-EVs) have therefore attracted increasing interest as a potential alternative strategy warranting systematic investigation.

DESIGN

This narrative review, structured around a systematic literature search, critically analyzes the biogenesis, molecular cargo, and mechanistic basis of DMSC-EVs. We address the essential conceptual distinction between extracellular vesicles and whole conditioned medium, then examine specific applications in dental pulp, periodontal, and alveolar bone regeneration, with particular emphasis on emerging engineering strategies-including genetic modification, preconditioning, and biomaterial-based delivery systems-designed to overcome the limitations of native EVs.

RESULTS

Inheriting the neural crest-derived regenerative potential of their parent cells, DMSC-EVs orchestrate tissue repair through three interconnected core mechanisms: immune microenvironment remodeling, angiogenesis-osteogenesis coupling, and neuroprotection. These pathways may interact functionally and could act synergistically in regenerative microenvironments. Emerging evidence from mineralization-related vesicle systems suggests that EVs may participate in hard-tissue biomineralization through vesicular trafficking of mineral-associated cargo; however, direct evidence for this mechanism in DMSC-EV-mediated oral regeneration remains limited. Engineering strategies show differential efficacy and clinical feasibility, with important tradeoffs to consider.

CONCLUSIONS

DMSC-EVs represent a promising preclinical cell-free approach in oral regenerative medicine, though the path to clinical translation requires resolving urgent challenges in isolation standardization, quality control, scalable production, and regulatory classification. Specific benchmarking frameworks and reporting standards tailored to oral regeneration applications are proposed.